Background
Methods
Study design
Selection of IHC markers
Tissue microarray
IHC analysis
Data process of protein expression profiles
Signature identification and model development
Statistical analysis
Results
Patient characteristics
Variable | All patients (n = 384) | BJ cohort (n = 211) | CQ cohort (n = 173) |
---|---|---|---|
Age | |||
≤60 | 151 (39.32%) | 73 (34.60%) | 78 (45.09%) |
> 60 | 233 (60.68%) | 138 (65.40%) | 95 (54.91%) |
Gender | |||
Male | 270 (70.31%) | 135 (63.98%) | 135 (78.03%) |
Female | 114 (29.69%) | 76 (36.02%) | 38(21.97%) |
Smoking index (pack years) | |||
Never smokers | 142 (36.98%) | 94 (44.55%) | 48 (27.75%) |
Light smokers (< 20) | 41 (10.68%) | 26 (12.32%) | 15 (8.67%) |
Heavy smokers (≥20) | 183 (47.65%) | 88 (41.71%) | 95 (54.91%) |
Unknown | 18 (4.69%) | 3 (1.42%) | 15 (8.67%) |
Histology | |||
Adenocarcinoma | 206 (53.65%) | 122 (57.82%) | 84 (48.55%) |
Squamous cell carcinoma | 178 (46.35%) | 89 (42.18%) | 89 (51.45%) |
Follow-up (months; median; IQR) | 58 (22–75) | 59 (19–74) | 56 (29–76) |
Deaths | 175 (45.57%) | 93 (44.07%) | 82 (47.40%) |
Differentiation grade | |||
Well | 75 (19.53%) | 45 (21.33%) | 30 (17.34%) |
Moderate | 140 (36.46%) | 67 (31.75%) | 73 (42.20%) |
Poor | 138 (35.94%) | 98 (46.45%) | 40 (23.12%) |
Unknown | 31 (8.07%) | 1 (0.47%) | 30 (17.34%) |
Pathologic stage | |||
I | 188 (48.96%) | 95 (45.02%) | 93 (53.76%) |
II | 101 (26.30%) | 47 (22.28%) | 54 (31.21%) |
III | 95 (24.74%) | 69 (32.70%) | 26 (15.03%) |
Adjuvant chemotherapy | |||
No | 141 (36.72%) | 100 (47.39%) | 41 (23.70%) |
Yes | 243 (63.28%) | 111 (52.61%) | 132 (76.30%) |
Identification of the ADC signature
Independent validation of the ADC signature
Histology | Variable | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
HR(95% CI) | P value | HR(95% CI) | P value | ||
ADC | Six-protein signaturea | 2.89 (1.52–5.48) | 0.001 | 3.07 (1.29–7.32) | 0.011 |
Stageb | 2.43 (1.64–3.60) | < 0.001 | 2.43 (1.46–4.03) | 0.001 | |
Age > 60 years | 1.33 (0.70–2.53) | 0.390 | 1.37 (0.65–2.87) | 0.413 | |
Tumor size | 1.09 (0.91–1.30) | 0.341 | 1.02 (0.84–1.24) | 0.880 | |
Smoking index | 1.01 (0.99–1.03) | 0.425 | 0.99 (0.97–1.01) | 0.426 | |
Chemotherapy | 1.09 (0.52–2.30) | 0.816 | 1.50 (0.61–3.67) | 0.379 | |
SCC | Five-protein signaturea | 10.84 (4.15–28.31) | < 0.001 | 7.84 (2.88–21.31) | < 0.001 |
Stageb | 2.85 (1.78–4.57) | < 0.001 | 2.24 (1.26–3.99) | 0.006 | |
Age > 60 years | 1.73 (0.86–3.50) | 0.127 | 1.48 (0.70–3.14) | 0.307 | |
Tumor size | 1.15 (1.00–1.32) | 0.058 | 1.02 (0.85–1.23) | 0.838 | |
Smoking index | 1.00 (0.99–1.01) | 0.994 | 1.00 (0.98–1.02) | 0.659 | |
Chemotherapy | 1.23 (0.56–2.71) | 0.615 | 1.45 (0.55–3.83) | 0.452 |